Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer

25 Jun 2025

Abstract excerpt

ABSTRACT: Loss-of-function (LoF) mutations frequently found in human cancers are generally intractable by classical small molecule inhibitor approaches. Among them are mutations affecting Polycomb-group (PcG) epigenetic regulators, enhancer of zeste homolog 2 (EZH2) and Additional sex combs like 1 (ASXL1), frequently found in hematological malignancies of myeloid or lymphoid lineage, and their concurrent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40561338
DOI: 10.1182/blood.2025028560

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancerPMID 40561338Read ↗

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomasSemantic proximity Read ↗

Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.Semantic proximity Read ↗

ASXL1/2 mutations and myeloid malignancies.Semantic proximity Read ↗

Polycomb complexes in normal and malignant hematopoiesisSemantic proximity Read ↗

A non-canonical EZH2 function sensitizes solid tumors to genotoxic stressSemantic proximity Read ↗

PRC2 Inactivating Mutations in Cancer are Synthetic Lethal with DNMT1 Targeted Therapy via Enhanced Viral MimicrySemantic proximity Read ↗

Chronic Myelogenous Leukemia– Initiating Cells Require Polycomb Group Protein EZH2Semantic proximity Read ↗

Polycomb Group Proteins: Multi-Faceted Regulators of Somatic Stem Cells and CancerSemantic proximity Read ↗

Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.Semantic proximity Read ↗

EZH2-associated tumor malignancy: A prominent target for cancer treatment.Semantic proximity Read ↗

Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancersSemantic proximity Read ↗

Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent mannerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.